VJHemOnc is committed to improving our service to you

BSH 2017 | How the treatment of AML will change

VJHemOnc is committed to improving our service to you

Mary F. McMullin

Mary Frances McMullin, MD of Belfast City Hospital, Belfast, UK discusses targeted therapy and immunotherapy for acute myeloid leukemia (AML) held at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Prof. McMullin explains that she was part of a discussion at BSH on targeted therapy and immunotherapy for AML. We are in the era of molecular medicine as our understanding of mutations underlying disease is improving and she explains that this may change the treatment of AML.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter